Exhibit 99.2

 Focused innovation  driving sustainable growth  Lundbeck Capital Markets Event – October 23, 2024  Martha  Living with depression and ADHD 

 Safe Harbor/Forward-Looking Statements  This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding the proposed acquisition of Longboard Pharmaceuticals, Inc. ("Longboard") by Lundbeck and Longboard's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to Lundbeck and Longboard's products), are forward looking statements.  Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause Lundbeck and Longboard's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations; delay or failure of development projects, production or distribution problems; unexpected contract breaches or terminations; government- mandated or market-driven price decreases for Lundbeck's products; introduction of competing products; Lundbeck's ability to successfully market both new and existing products; exposure to product liability and other lawsuits; changes in reimbursement rules and governmental laws and related interpretation thereof; and unexpected growth in costs and expenses. Additional risks and uncertainties include, but are not limited to, risks related to Lundbeck’s ability to complete the transaction on the proposed terms and schedule; whether the tender offer conditions will be satisfied; whether sufficient stockholders of Longboard tender their shares in the transaction; the outcome of legal proceedings that may be instituted against Longboard and/or others relating to the transaction; the failure to receive (or delay in receiving) the required regulatory approvals relating to the transaction; the possibility that competing offers will be made; risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; risks related to future opportunities and plans for Longboard and its products, including uncertainty of the expected financial performance of Longboard and its products; disruption from the proposed transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the occurrence of any event, change or other circumstance that could give rise to the termination of the acquisition agreement; and other uncertainties pertaining to the business of Longboard, including those detailed in Longboard’s public filings with the SEC from time to time, including Longboard’s most recent Annual Report on Form 10-K for the year ended December 31, 2023 and its subsequent Quarterly Reports on Form 10-Q. The reader is cautioned not to unduly rely on these forward-looking statements. The forward-looking statements in this company presentation and any oral presentations speak only as at the date of this presentation. Lundbeck disclaims any intent or obligation to update or revise these forward-looking statements, or to confirm such statements to reflect subsequent events or circumstances after the date of the company release or in relation to actual results, other than as may be required under applicable law or applicable stock exchange regulations.  Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with products that are prescribed for unapproved uses, are made considering past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.  3  Capital Markets Event – October 23, 2024 

 IMPORTANT INFORMATION FOR INVESTORS AND SECURITY HOLDERS  The tender offer (the Offer) for the outstanding common stock of Longboard referred to in this presentation has not yet commenced. The description contained in this presentation is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Lundbeck and its acquisition subsidiary will file with the U.S. Securities and Exchange Commission (the SEC). The solicitation and offer to buy the common stock of Longboard will only be made pursuant to an offer to purchase and related tender offer materials. At the time the Offer is commenced, Lundbeck will file a tender offer statement on Schedule TO and thereafter Longboard will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the Offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. ANY HOLDERS OF SHARES ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.  The offer to purchase, the related letter of transmittal and the solicitation/recommendation statement will be made available for free at the SEC’s website at www.sec.gov. Free copies of the offer to purchase, the related letter of transmittal and certain other offering documents will be made available by Lundbeck and when available may be obtained by directing a request to the Information Agent for the tender offer which will be named in the Schedule TO. Copies of the documents filed with the SEC by Longboard will be available free of charge on Longboard’s internet website https://ir.longboardpharma.com/financial- information/sec-filings or by contacting Longboard’s investor relations contact at IR@LongboardPharma.com.  In addition to the offer to purchase, the related letter of transmittal and certain other tender offer documents filed by Lundbeck, as well as the solicitation/recommendation statement filed by Longboard, Longboard will also file annual, quarterly and current reports with the SEC. You may read and copy any reports or other information filed by Lundbeck or Longboard at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Longboard’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at http://www.sec.gov.  4  Capital Markets Event – October 23, 2024 

 Majority of DEEs have no approved treatment options  Numbers from U.S. Dravet Syndrome Foundation and U.S. LGS Foundation. Longboard Pharmaceuticals subject to deal closure. Expected December 2024.  DEE: Developmental and Epileptic Encephalopathies; TSC: Tuberous Sclerosis Complex; CDKL5: Cyclin Dependent Kinase Like 5; EMAS: Epilepsy with Myoclonic-Atonic Seizures.  Bexicaserin has the potential to address all DEEs  U.S. patient population of approximately 220,000 and half not served by licensed therapies  Sizable opportunities across all DEEs  DEEs without approved drugs  Approximately 100,000 patients  DEEs with approved drugs  Approximately 120,000 patients  Lennox-Gastaut syndrome  44  Capital Markets Event – October 23, 2024  Dravet syndrome  Other DEEs  Bexicaserin  Pipeline in a mechanism 

 Bexicaserin in phase III backed by strong clinical data  A differentiated, highly selective 5-HT2C agonist with a compelling efficacy and safety profile  5-HT: 5-hydroxytryptamine (serotonin) receptors; VHD: Valvular Heart Disease; PAH: Pulmonary Arterial Hypertension; SAD: Single Ascending Dose; CSF: Cerebrospinal Fluid; EEG: Electroencephalogram. Longboard Pharmaceuticals subject to deal closure. Expected December 2024.  Greater selectivity and specificity  Designed to only bind 5-HT2C receptors  No detected activity at receptors associated with significant adverse events with either  5-HT2B (VHD and PAH) or 5-HT2A (psychiatric)  Bexicaserin  Pre-clinical evidence  Reduced seizure, epileptiform activity, duration and number of epileptiform events in fish and rodent models  Phase I – Healthy volunteers  No observed food effect in SAD trial  Plasma & CSF concentration increased in a dose-dependent & consistent manner  Phase II – Multiple DEE populations (PACIFIC)  Topline data communicated in Q1 2024  Global phase III program initiated in Q4 2024  Recent 9-month open-label data confirms strong and durable seizure reduction of 57.7% in countable motor seizures  45  Capital Markets Event – October 23, 2024 

 Sustainable effects shown in open-label extension study  More than 50% reduction across treatment groups  Longboard Pharmaceutical Investor & Analyst Day September 16, 2024. Longboard Pharmaceuticals subject to deal closure. Expected December 2024.  Median percent reduction in monthly seizure frequency from PACIFIC baseline  9-month open-label extension (OLE)  Transition to OLE  Month 2  -100  -80  0  -40  -60  -20  Month 3  Month 4  Month 5  Month 6  Month 7  Month 8  Month 9  Month 1  50% reduction  Bexicaserin PACIFIC to bexicaserin OLE Placebo PACIFIC to bexicaserin OLE  Overall  PACIFIC  data set  48  Capital Markets Event – October 23, 2024 

 Continued growth from in-market assets to organic pipeline  Building on strong mid-term momentum to secure future long-term growth  (1) Revenue forecasts for amlenetug, anti-PACAP and bexicaserin are not risk-adjusted; (2) Subject to deal closure. Expected December 2024.  Figures in constant exchange rates. Expected outlook and figures exclude any potential additional business development activities beyond Longboard Pharmaceuticals acquisition.  PACAP: Pituitary Adenylate Cyclase-Activating Peptide; PTSD: Post-Traumatic Stress Disorder.  Vyepti  Tripling of sales  Rexulti  Mid-teen-digit CAGR excl. PTSD potential  Amlenetug  Anti-PACAP  Bexicaserin2  Revenue ambition  Illustrative  Mature brands Strategic brands  Mid-term – Solid growth driven by Vyepti and Rexulti  Pipeline assets1  2023  Acceleration  Generic  Operating model  2027  Acceleration  Generic  Late-stage  Bexicaserin1,2  Beyond  erosion  optimization  erosion  pipeline1  2030  Rexulti  Brintellix  Abilify Maintena  Mature brands  + Amlenetug  + Anti-PACAP  + Vyepti  + Rexulti  Abilify Maintena  Brintellix  Mature brands  + Vyepti  More than  DKK 30bn  Additional growth from early-stage pipeline and potential business development activities  Operating model optimization  Long-term ambition – Innovative late-stage pipeline  59  Capital Markets Event – October 23, 2024  20 

 Allocating resources to ensure sustainable growth  How do we fund our growth ambitions?  Share buyback  Dividend  Balance sheet  Options in focus  Business development  Longboard Pharmaceuticals1  …  Excess resources  Early-stage development and building a sustainable pipeline  Late-stage pipeline progression  Continuous growth of Vyepti  Exploiting full potential of Rexulti  Organic uses of capital  Targeted divestments  Operational effectiveness  Commercial model optimization  Acceleration of strategic brands  Organic sources of capital  (1) Subject to deal closure. Expected December 2024.  60  Capital Markets Event – October 23, 2024 

 Largest capital reallocation program in Lundbeck’s history  Improving margins while funding our future  2023 base  2027 organic  Costs1  Adj. EBITDA  Revenue  Capital reallocation program  Organic sources of capital Organic uses of capital  EBITDA impact in 2027  One-off costs 2024-2027  Appr. DKK -1bn2  Appr. DKK 1-1.3bn  Appr. DKK -0.5bn  Acceleration of strategic brands  Commercial model optimization  Production model optimization  Production model optimization  Commercial model optimization Brand profitability spend  Cost efficiencies  ~72%  28.4%  DKK 20bn  Improved by 2-4pp  30-32%  Mid-single digit CAGR  Acceleration of strategic brands  Focused investments in R&D  Inflow / increase in capital  Outflow / decrease in capital  Illustrative  (1) Excluding depreciation and amortization costs, and one-off costs (incl. restructuring and integration costs); (2) Includes appr. DKK 0.5bn for MAGLi74 impairment. Expected outlook and figures exclude any potential additional business development activities beyond Longboard Pharmaceuticals acquisition.  61  Capital Markets Event – October 23, 2024 

 Largest capital reallocation program in Lundbeck’s history  Improving margins while funding our future  2023 base  2027 organic  Costs1  Adj. EBITDA  Revenue  Capital reallocation program  Organic sources of capital Organic uses of capital  EBITDA impact in 2027  One-off costs 2024-2027  Appr. DKK -1bn2  Appr. DKK 1-1.3bn  Appr. DKK -0.5bn  Acceleration of strategic brands  Commercial model optimization  Production model optimization  Focused investments in R&D  Acceleration of strategic brands  Production model optimization  Commercial model optimization Brand profitability spend  Cost efficiencies  Improved by ~2pp  >30%  Mid-single digit CAGR  2027 target  Longboard3  ~72%  28.4%  DKK 20bn  Improved by 2-4pp  30-32%  Mid-single digit CAGR  Pre-launch commercial spend for bexicaserin3  R&D spend for bexicaserin phase III trial  Appr. DKK -0.6bn  Appr. DKK -0.7bn  Organic uses of capital  Inflow / increase in capital  Outflow / decrease in capital  Illustrative  (1) Excluding depreciation and amortization costs, and one-off costs (incl. restructuring and integration costs); (2) Includes appr. DKK 0.5bn for MAGLi74 impairment; (3) Subject to deal closing. Expected December 2024. Expected outlook and figures exclude any potential additional business development activities beyond Longboard Pharmaceuticals acquisition.  62  Capital Markets Event – October 23, 2024 

 Mid-term guidance backed by clarity on strategic drivers  Profitable and sustainable organic growth  Expected outlook and figures exclude any potential additional business development activities beyond Longboard Pharmaceuticals acquisition. Longboard Pharmaceuticals subject to deal closure. Expected December  Mid-term guidance 2027  Total revenue growth (%)  Adjusted EBITDA margin (%)  More than 30%  Mid-single-digit CAGR through 2027  High single-digit CAGR for strategic brands through 2027  Key drivers  Expect to triple sales by 2027 driven by strong patient-focused ecosystem  Mid-teen-digit CAGR until 2027 excl. potential upside from PTSD  Sales and distribution ratio  Commercial go-to-market model optimization leading to steadily decreasing ratio towards 30-35% of revenues (37.6% in 2023)  R&D ratio  Steady increase of R&D spend towards 20-25% of revenues (17.4% in 2023) and strengthening of pipeline towards sustainable shape  2024. PTSD: Post-Traumatic Stress Syndrome.  64  Capital Markets Event – October 23, 2024